1-methyl-4-phenyl-2,3-dihydropyridinium has been researched along with norharman in 1 studies
| Studies (1-methyl-4-phenyl-2,3-dihydropyridinium) | Trials (1-methyl-4-phenyl-2,3-dihydropyridinium) | Recent Studies (post-2010) (1-methyl-4-phenyl-2,3-dihydropyridinium) | Studies (norharman) | Trials (norharman) | Recent Studies (post-2010) (norharman) |
|---|---|---|---|---|---|
| 46 | 0 | 3 | 364 | 2 | 153 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herraiz, T | 1 |
1 other study(ies) available for 1-methyl-4-phenyl-2,3-dihydropyridinium and norharman
| Article | Year |
|---|---|
Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Chromatography, High Pressure Liquid; Clorgyline; Enzyme Assays; Harmine; Humans; Indazoles; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Nicotiana; Oxidation-Reduction; Pyridinium Compounds; Recombinant Proteins; Selegiline; Smoke; Vitamin K 3 | 2012 |